TY - JOUR
T1 - SLCO1B1
T2 - Application and limitations of deep mutational scanning for genomic missense variant function
AU - Zhang, Lingxin
AU - Sarangi, Vivekananda
AU - Ho, Ming Fen
AU - Moon, Irene
AU - Kalari, Krishna R.
AU - Wang, Liewei
AU - Weinshilboum, Richard M.
N1 - Funding Information:
This study was funded by National Institutes of Health (NIH) National Institute of General Medical Sciences (NIGMS) [Grant U19-GM61388] (The Pharmacoge-nomics Research Network), NIGMS [Grant R01-GM28157]; NIH National Institute on Alcohol Abuse and Alcoholism (NIAAA) [Grant R01-AA27486] and [Grant K01-AA2850], NIGMS [Grant R01-GM125633], and the Mayo Clinic Center for Individualized Medicine. https://doi.org/10.1124/dmd.120.000264. s This article has supplemental material available at dmd.aspetjournals.org.
Publisher Copyright:
Copyright © 2021 by The Author(s)
PY - 2021/5/1
Y1 - 2021/5/1
N2 - SLCO1B1 (solute carrier organic anion transporter family member 1B1) is an important transmembrane hepatic uptake transporter. Genetic variants in the SLCO1B1 gene have been associated with altered protein folding, resulting in protein degradation and decreased transporter activity. Next-generation sequencing (NGS) of pharmacogenes is being applied increasingly to associate variation in drug response with genetic sequence variants. However, it is difficult to link variants of unknown significance with functional phenotypes using “one-at-a-time” functional systems. Deep mutational scanning (DMS) using a “landing pad cell–based system” is a high-throughput technique designed to analyze hundreds of gene open reading frame (ORF) missense variants in a parallel and scalable fashion. We have applied DMS to analyze 137 missense variants in the SLCO1B1 ORF obtained from the Exome Aggregation Consortium project. ORFs containing these variants were fused to green fluorescent protein and were integrated into “landing pad” cells. Florescence-activated cell sorting was performed to separate the cells into four groups based on fluorescence readout indicating protein expression at the single cell level. NGS was then performed and SLCO1B1 variant frequencies were used to determine protein abundance. We found that six variants not previously characterized functionally displayed less than 25% and another 12 displayed approximately 50% of wild-type protein expression. These results were then functionally validated by transporter studies. Severely damaging variants identified by DMS may have clinical relevance for SLCO1B1-dependent drug transport, but we need to exercise caution since the relatively small number of severely damaging variants identified raise questions with regard to the application of DMS to intrinsic membrane proteins such as organic anion transporter protein 1B1.
AB - SLCO1B1 (solute carrier organic anion transporter family member 1B1) is an important transmembrane hepatic uptake transporter. Genetic variants in the SLCO1B1 gene have been associated with altered protein folding, resulting in protein degradation and decreased transporter activity. Next-generation sequencing (NGS) of pharmacogenes is being applied increasingly to associate variation in drug response with genetic sequence variants. However, it is difficult to link variants of unknown significance with functional phenotypes using “one-at-a-time” functional systems. Deep mutational scanning (DMS) using a “landing pad cell–based system” is a high-throughput technique designed to analyze hundreds of gene open reading frame (ORF) missense variants in a parallel and scalable fashion. We have applied DMS to analyze 137 missense variants in the SLCO1B1 ORF obtained from the Exome Aggregation Consortium project. ORFs containing these variants were fused to green fluorescent protein and were integrated into “landing pad” cells. Florescence-activated cell sorting was performed to separate the cells into four groups based on fluorescence readout indicating protein expression at the single cell level. NGS was then performed and SLCO1B1 variant frequencies were used to determine protein abundance. We found that six variants not previously characterized functionally displayed less than 25% and another 12 displayed approximately 50% of wild-type protein expression. These results were then functionally validated by transporter studies. Severely damaging variants identified by DMS may have clinical relevance for SLCO1B1-dependent drug transport, but we need to exercise caution since the relatively small number of severely damaging variants identified raise questions with regard to the application of DMS to intrinsic membrane proteins such as organic anion transporter protein 1B1.
UR - http://www.scopus.com/inward/record.url?scp=85104275777&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85104275777&partnerID=8YFLogxK
U2 - 10.1124/dmd.120.000264
DO - 10.1124/dmd.120.000264
M3 - Article
C2 - 33658230
AN - SCOPUS:85104275777
SN - 0090-9556
VL - 49
SP - 395
EP - 404
JO - Drug Metabolism and Disposition
JF - Drug Metabolism and Disposition
IS - 5
ER -